KYMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kymera Therapeutics Inc (KYMR) is not a strong buy for a beginner, long-term investor at this time. While analysts maintain a generally positive outlook with high price targets, the lack of recent positive news, insider selling, poor financial performance in the latest quarter, and no strong trading signals suggest that this is not an optimal entry point. The investor should wait for clearer catalysts or improved financial and technical indicators before committing to this stock.
The MACD is negative and contracting, RSI is neutral at 54.221, and moving averages are converging, indicating no clear trend. The stock is trading near the pivot level of 78.155, with resistance at 81.65 and support at 74.66. Overall, the technical indicators suggest a neutral to slightly bearish sentiment.
Analysts maintain high price targets, with multiple buy ratings and optimism about Kymera's lead STAT6 degrader program and its potential to disrupt the immunology market. Piper Sandler highlights Kymera's first-mover advantage and attractive risk-reward profile.
Insiders are selling heavily, with a 627.73% increase in selling activity over the last month. Financial performance in Q4 2025 was weak, with a 61.18% drop in revenue and negative net income. Wolfe Research downgraded the stock, citing valuation concerns and lack of catalysts.
In Q4 2025, revenue dropped by 61.18% YoY to $2.87M. Net income improved slightly but remains negative at -$86.98M. EPS increased to -0.97, up 10.23% YoY. Gross margin remained at 100%. Overall, the company is not showing strong financial growth.
Analysts are generally positive, with multiple buy ratings and price targets ranging from $100 to $140. However, Wolfe Research downgraded the stock, citing valuation concerns and lack of immediate catalysts.
